Navigation Links
GlaxoSmithKline and Cellzome Announce Major Strategic Alliance

Kinobeads(TM) Technology to Identify a New Generation of Drug Candidates

for Inflammatory Diseases

LONDON and CAMBRIDGE, England and PHILADELPHIA and HEIDELBERG, Germany, September 10 /PRNewswire/ -- Cellzome Inc. and GlaxoSmithKline (LSE & NYSE: GSK) announce the signing of a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases.

The alliance gives GSK access to Cellzome's significant expertise in identifying and developing selective kinase inhibitors and its proprietary Kinobeads(TM) technology which, by screening compounds in a physiological setting, is designed to improve the predictability of these drug candidates' performance in clinical testing. Kinases are key molecular switches in cellular signaling events with a central role in many inflammatory responses and selective inhibitors offer a different approach to therapeutic intervention in diseases such as rheumatoid arthritis or multiple sclerosis.

Under the agreement GSK has exclusive options to license drug candidates from Cellzome's kinase programs directed against four identified targets, and three additional targets to be jointly identified by both parties. In the alliance, Cellzome will utilize its proprietary Kinobeads(TM) technology to discover novel small molecule inhibitors of these targets, and then will develop the most promising product candidates through to completion of a clinical proof of concept trial, unless GSK elects to exercise its option earlier. Cellzome is eligible to receive success-based milestones from GSK as product candidates are advanced. Upon Cellzome's achievement of clinical proof of concept for a product candidate for a particular kinase target, GSK would have an exclusive option to license all product candidates from that program. GSK would then assume full responsibility for further clinical development and commercialization on a worldwide basis. Cellzome retains the right to continue the development and commercialization of drug candidates if GSK chooses not to exercise its option to that program.

Under the terms of the agreement, Cellzome will receive upfront payments of GBP14.4 million comprised of both cash and equity. Cellzome is eligible for up to GBP118 million per program in potential development, regulatory and commercial milestones and up to double digit royalties on net sales of products resulting from the alliance.

Jose Carlos Gutierrez-Ramos, Ph.D, Senior Vice President and Head of the Immuno-Inflammation Centre of Excellence for Drug Discovery of GSK said: "GSK is committed to becoming a world leader in immuno-inflammation drug discovery by finding transformative medicines through internal efforts and external collaborations. We are excited to be working with Cellzome to discover and develop improved approaches to existing biologic therapies which cannot access intracellular signaling mechanisms. Cellzome's Kinobeads(TM) technology will provide a distinct advantage because it uses native kinases directly isolated from human cells and tissues."

Tim Edwards, CEO of Cellzome, said: "We are very pleased to begin a strategic alliance with GSK, one of the world's leading pharmaceutical R&D companies. This alliance is a significant endorsement of our leading Kinobeads(TM) technology, programs and people. It is a major event in Cellzome's development, giving us the opportunity to broaden our pipeline and progress several kinase programs towards the clinic, ultimately for the benefit of patients."

About Cellzome Inc.

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads(TM), a proprietary technology for screening and profiling kinases in relevant cells and tissues.

Cellzome is applying its distinctive Kinobeads(TM) technology to the discovery and development of innovative small-molecule kinase inhibitors targeting key inflammatory mediators such as PI3Kg and d, Zap-70, Jak3 and mTOR, as potential oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and asthma.

In addition to the GSK collaboration, Cellzome has an alliance with Johnson & Johnson focused on the discovery of novel medicines for the treatment of Alzheimer's disease. Cellzome's holding company is domiciled in the US and it employs about 90 people at its two operating subsidiaries in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website:

About GlaxoSmithKline (LSE & NYSE: GSK)

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For detailed company information, see GlaxoSmithKline's website:

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2007.

About Kinases

Kinases are important enzymes because they are responsible for either activating or inhibiting proteins within cell signaling pathways. As a result of their importance, approximately 30% of current discovery and development spending focuses on kinases, especially in the fields of oncology, inflammation and metabolic diseases. Despite this level of interest and research, only 8 small molecule kinase inhibitors have so far reached the market, all of them targeting oncology indications.

For further information please contact:

Cellzome Enquiries:

Cellzome Inc., Cellzome Limited and Cellzome AG

Tim Edwards

Chief Executive Officer

+49(0)6221-137 57-100

Media Contact for Cellzome

The Hogarth Partnership

Sarah MacLeod


GSK Enquiries:

UK Media enquiries: Philip Thomson +44(0)20-8047-5502

Claire Brough +44(0)20-8047-5502

Alice Hunt +44(0)20-8047-5502

Gwenan White +44(0)20-8047-5502

US Media enquiries Nancy Pekarek +1-215-751-7709

Mary Anne Rhyne +1-919-483-2839

Sarah Alspach +1-215-751-7709

European Analyst/Investor David Mawdsley +44(0)20-8047-5564


Sally Ferguson +44(0)20-8047-5543

Gary Davies +44(0)20-8047-5503

US Analyst/ Investor

enquiries: Frank Murdolo +1-215-751-7002

Tom Curry +1-215-751-5419

SOURCE Cellzome Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
2. GlaxoSmithKline To Post Quarterly US Grants Report
3. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
4. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
5. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
6. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
7. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
8. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
9. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
10. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
11. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
Post Your Comments:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s Medical ... place on 7th and 8th June 2018 in San Francisco, CA. The Summit brings ... well as several distinguished CEOs, board directors and government officials from around the world ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... October 10, 2017 , ... For ... has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled ... Volunteer Experience from US2020. , US2020’s mission is to change the trajectory of ...
Breaking Biology Technology:
(Date:7/20/2017)... 20, 2017 Delta (NYSE: DAL ) customers now ... aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at ... Delta,s biometric boarding pass experience ... is now integrated into the boarding process to allow eligible Delta SkyMiles ...
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
Breaking Biology News(10 mins):